New size brings innovative planter to a wider range of smaller operations. At a Glance: The Fendt® Momentum® 30-Foot Planter The new 30-foot Fendt Momentum planter brings its agronomically advanced planting system to a whole new range of smaller opera
DUBLIN--(BUSINESS WIRE)--The "Frozen Yogurts - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The global frozen yogurt market analysis spans various geographic regions, highlighting market presence, key compe
HALIFAX, Canada--(BUSINESS WIRE)--Mara Renewables Corporation, and its manufacturing partner Algal Omega-3 (AO3) announced today they have filed a second IPR in the United States challenging DSM Patent No. 10757959 “Thraustochytrids, fatty acid composit
MONTREAL--(BUSINESS WIRE)--#compoundingpharmacy--In 2018, Medisca, a global leader in pharmaceutical compounding and personalized medicine, partnered with the Université Laval Faculty of Medicine located in Quebec, Canada. The commitment included funding
LAVAL, Quebec--(BUSINESS WIRE)--Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”) announced today that the Toronto Stock Exchange (the “TSX”) has approved the Company’s proposed normal course issuer bid (“
MONTREAL--(BUSINESS WIRE)--Laurent Pharmaceuticals Inc., a Montreal-based biopharmaceutical company, today announced that it has obtained the approval from Health Canada to initiate ESSOR, an adaptive Phase 2/3 randomized placebo-controlled trial testing
VAUGHAN, Ontario--(BUSINESS WIRE)--Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders is scheduled to participate at t
Composition of matter and methods of use claims encompass EB-373, Enveric’s new chemical entity psilocin prodrug being developed for the treatment of anxiety disorderCAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” o
- All-share transaction creates international clinical-stage leader in novel psychedelic therapeutics - - Two proprietary, advanced clinical programs in development for depression and anxiety disorders with demonstrated safety and efficacy - - Combined p
TORONTO--(BUSINESS WIRE)--Jack Nathan Medical Corp. (TSXV: JNH, OTCQB: JNHMF) (“Jack Nathan Health” or the “Company”) is pleased to announce the appointment of Mr. Bharat Choudhary as the Company’s new permanent Chief Financial Officer (CFO). Th
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.